Office Of Cancer Complementary And Alternative Medicine .
National Cancer InstituteOffice of Cancer Complementary and Alternative MedicineANNUAL REPORT ONComplementary and Alternative MedicineFISCAL YEAR 2009U.S. DEPARTMENTOF HEALTH ANDHUMAN SERVICESNational Institutesof Health
DIRECTOR’S MESSAGEThe research the National Cancer Institute (NCI)supports, both in our own laboratories and atinstitutions worldwide, is focused on the ultimategoal of helping cancer patients. That mission –achieved through rigorous science – extends toNCI’s program on complementary and alternative medicine, also known as CAM.It is with great pleasure and pride that we onceagain provide NCI’s research partners, physicians, the advocacy community, policymakersand cancer patients with this fifth annual reviewof NCI’s extensive accomplishments in advancingevidence-based CAM interventions and therapies.Fiscal year (FY) 2009, marked the 10th anniversary of the establishment of NCI’s Office ofCancer Complementary and AlternativeMedicine (OCCAM). Since its creation, OCCAMhas held the job of coordinating and fostering theInstitute’s CAM research portfolio and partnerships with extramural researchers as well aswithin NCI’s intramural programs.Over the past ten years, NCI’s portfolio of CAMresearch grew from about 20 million to around 120 million. This growth has been due to thehard work of hundreds of cancer researchersaround the world as well as many individualsthroughout the NCI, including OCCAM’sefforts in developing new funding opportunities,enhancing CAM technical assistance to grantapplicants, and creating collaborative partnerships. There also has been substantial growthin the number of clinical trials relevant to CAMtherapies, including landmark studies whichfor the first time provided solid evidence thatimprovements in lifestyle and dietary interventions are feasible and can impact the recurrenceof certain cancers.NCI’s commitment to CAM research and clinicalpractice has been steadily supported, coordinated, and expanded by OCCAM over the years.That mission is continuing with the identificationof new research priorities for NCI’s CAM office.OCCAM’s new priorities will expand NCI’sability to extend the search for effective therapiesinto areas outside the mainstream of conventionalbiomedical research.I hope you find this report helpful and informative. I also hope that it will generate an enhanceddialogue – especially between patients and healthcare professionals – about the appropriate uses ofCAM interventions in conjunction with conventional medicine. Cancer patients deserve credible,unbiased information about any intervention ortreatment regimen that they are considering. It isour duty to conduct and support the science thatmakes wise and informed decisions possible.Jeffrey D. White, M.D.DirectorOffice of Cancer Complementary and Alternative MedicineDivision of Cancer Treatment and DiagnosisNational Cancer InstituteNCI CAM ANNUAL REPORT 20091
The following acronyms are used throughout this report:NCINational Cancer InstituteCAMcomplementary and alternative medicineOCCAMOffice of Cancer Complementary and Alternative MedicineFYfiscal yearNIHNational Institutes of HealthDCBDivision of Cancer BiologyDCCPSDivision of Cancer Control and Population SciencesDCPDivision of Cancer PreventionDCTDDivision of Cancer Treatment and DiagnosisCCRCenter for Cancer ResearchDCEGDivision of Cancer Epidemiology and GeneticsARRAAmerican Recovery and Reinvestment ActDOCDivisions, Offices and CentersTCMTraditional Chinese MedicineMOUMemorandum of UnderstandingNPBNatural Products BranchDTPDevelopmental Therapeutics ProgramCSCcancer stem cellsRDSPResearch Development and Support ProgramPAprogram announcementCCOPCommunity Clinical Oncology ProgramCARRAConsumer Advocates in Research and Related ActivitiesCOPCommunications and Outreach ProgramPAPPractice Assessment ProgramBCSBest Case SeriesCISCancer Information ServicePDQPhysician Data QuerySQFSheng Qi FormulaNDNaturopathic DoctorFOAfunding opportunity announcementCDCCenters for Disease Control and PreventionPMIDPubMed Identifier
CONTENTSDirector’s MessageIntroductionOffice of Cancer Complementary and Alternative Medicine (OCCAM)NCI CAM Communications ProgramsTraining and ConferencesHIGHLIGHTS FROM NCI’S CAM TRAINING PROJECTSNCI Supports Mentoring Program in Psychoneuroimmunology ResearchMentoring Helps Researcher Pursue Study of Ginger for Preventing Colorectal CancerNaturopathic Doctor Studies Antioxidant Use in Breast Cancer Patients156162226282930NCI Research in Complementary and Alternative MedicineNCI CAM RESEARCH PORTFOLIO ANALYSIS: FY 2009HIGHLIGHTS FROM NCI’S WIDE-RANGING CAM RESEARCH323538Understanding the Causes and Mechanisms of CancerPooling Resources to Examine Associations Between Vitamin D and Risk of Rarer CancersLarge Populations and Rigorous Methods Needed for Vitamin D ResearchTargeting Prostate Cancer Cells with BioflavonoidsTraditional Chinese Mind-Body Practice Studied in Long-Term Cancer SurvivorsTraditional Chinese Medicine Oil Studied Against Prostate Cancer404142434446Accelerating Progress in Cancer PreventionWest African Plants Studied for Inflammation and Cancer PreventionExercise May Boost the Immune System and Improve Cancer Vaccine EffectivenessRed Algae from the Sea Studied for Colon Cancer PreventionPomegranate Studied as Preventive Agent Against Prostate CancerDietary Components May Help Colon Cancer by Targeting InflammationCranberry Juice Shows Promise for the Prevention of Bladder CancerAncient Medicine from India Studied to Prevent Prostate Cancer4849505152535455Developing Effective and Efficient TreatmentsVitamin K Studied in Treatment and Prevention of Liver CancerVitamin D Studied to Treat Advanced Prostate CancerDietary Restrictions Treat Cancer as a Metabolic DiseaseExercise and Antidepressants May Counteract Stress-induced Tumor GrowthEnhancing Cancer Immunoprevention and Immunotherapy with Naturally Occurring Beta GlucansBotanical Products Examined for Prevention of Endometrial Cancer From Tamoxifen Treatment56575859606162Improving the Quality of Life for Cancer Patients, Survivors, and their FamiliesCranial Stimulation Tried for Managing Side Effects of Chemotherapy in Breast CancerExercise Intervention Studied for Heart Failure in Cancer SurvivorsSCIENTIFIC PUBLICATIONSAppendix6364656668NCI CAM ANNUAL REPORT 20093
FIGURE 1. MAJOR CATEGORIES OF CAM THERAPIESALTERNATIVE MEDICAL SYSTEMSNUTRITIONAL THERAPEUTICSDEFINITION: Alternative medical systems are built upon completeDEFINITION: Nutritional therapeutics are an assortment ofsystems of theory and practice. Often, these systems have evolvednutrients and non-nutrients, bioactive food components used asapart from and earlier than the conventional medical approach usedchemo-preventive agents, and specific foods or diets used as cancerin the United States.prevention or treatment strategies.EXAMPLES: Acupuncture, Ayurveda, Homeopathy, Naturopathy,EXAMPLES: Macrobiotic diet, Vegetarianism, Gerson therapy,Traditional Chinese Medicine, Tibetan MedicineKelley/Gonzalez regimen, Vitamins, Soy phytoestrogens,Antioxidants, Selenium, Coenzyme Q10ENERGY THERAPIESDEFINITION: Energy therapies involve the use of energy fields.PHARMACOLOGICAL AND BIOLOGIC TREATMENTSThere are two types:DEFINITION: Pharmacological and biologic treatments include the Biofield therapies are intended to affect energy fields thatoff-label use of prescription drugs, hormones, complex naturalpurportedly surround and penetrate the human body. The existenceproducts, vaccines, and other biological interventions not yetof such fields has not yet been scientifically proven.accepted in mainstream medicine.EXAMPLES: Qi gong, Reiki, Therapeutic touchEXAMPLES: Antineoplastions, 714X, Low dose naltrexone, Electromagnetic-based therapies involve the unconventional useImmunoaugmentative therapy, Laetrile, Hydrazine sulfate,of electromagnetic fields, such as pulsed fields, magnetic fields, orMelatoninalternating current or direct current fields.EXAMPLES: Pulsed electromagnetic fields, Magnet therapyCOMPLEX NATURAL PRODUCTSDEFINITION: Complex natural products are an assortment ofEXERCISE THERAPIESplant samples (botanicals), extracts of crude natural substances,DEFINITION: Exercise therapies include health-enhancing systemsand un-fractionated extracts from marine organisms used forof exercise and movement.healing and treatment of disease.EXAMPLES: T’ai chi, Yoga asanasEXAMPLES: Herbs and herbal extracts, Mistletoe, Mixtures oftea polyphenols, Shark cartilageMANIPULATIVE AND BODY-BASED METHODSDEFINITION: Manipulative and body-based methods in CAM areSPIRITUAL THERAPIESbased on manipulation and/or movement of one or more parts ofDEFINITION: Spiritual therapies are therapies that focus on deep,the body.often religious beliefs and feelings, including a person’s sense ofEXAMPLES: Chiropractic, Therapeutic massage, Osteopathy,peace, purpose, connection to others, and beliefs about the meaningReflexologyof life.EXAMPLES: Intercessory prayer, Spiritual healingMIND-BODY INTERVENTIONSDEFINITION: Mind-body medicine uses a variety of techniquesdesigned to enhance the mind’s capacity to affect bodily functionand symptom.EXAMPLES: Meditation, Hypnosis, Art therapy, Biofeedback,Imagery, Relaxation therapy, Support groups, Music therapy,Cognitive-behavioral therapy, Aromatherapy
INTRODUCTIONEach year, Congress requests a report of theNational Cancer Institute’s (NCI) annual expenditures in complementary and alternative medicine (CAM)* research. To give more meaningto the numbers provided to Congress, a moredetailed account of the Institute’s investment inCAM has been produced for the last four years.The reports, (including last year’s NCI’s AnnualReport on Complementary and AlternativeMedicine: Fiscal Year 2008), are intended as away for NCI to communicate its progress in thisarea of medical research, not only to Congressbut also to other interested stakeholders including cancer researchers, CAM practitioners, healthcare providers, advocacy organizations, cancerpatients, and the general public.The NCI’s Office of Cancer Complementary andAlternative Medicine (OCCAM) is proud topresent the latest such report, NCI’s AnnualReport on Complementary and AlternativeMedicine: Fiscal Year 2009. Similar to theprevious reports, this publication provides anoverview of the NCI-supported work in thisfield along with details on certain selectedprojects in the areas of cancer CAM relatingto communication, training and conferences,and research.This report highlights projects, grants, andcooperative agreements supported by each ofthe Institute’s extramural grant funding divisions– Division of Cancer Biology (DCB), Division ofCancer Control and Population Sciences (DCCPS), Division of Cancer Prevention (DCP), andthe Division of Cancer Treatment and Diagnosis(DCTD), along with projects from NCI’s intramural laboratories – Center for Cancer Research(CCR) and the Division of Cancer Epidemiologyand Genetics (DCEG). These projects representa variety of CAM categories, cancer types,research types, and grant mechanisms. Thisreport includes summaries of selected traininggrant awards, as well as a breakdown of NCI’sCAM research portfolio. In fiscal year (FY) 2009,NCI’s research expenditures for CAM were anestimated 114,441,501 for the funding of 429CAM research projects. In addition, during FY2009, NCI used 21,637,877 in funds fromthe American Recovery and Reinvestment Act(ARRA) to award 104 CAM research grants.As this report on cancer CAM indicates, we atthe NCI are committed to an integrated approachto marshalling all of the many resources andapproaches necessary to make cancer a conditionthat is – at worst – a manageable, chronic illnesssimilar to heart disease and diabetes. We believethat evidence-based CAM techniques, systems,and products can have an important role inhelping us reach that worthwhile goal.* CAM is often defined as any medical system, practice, or product that is not thought of as “western medicine” or standard medicalcare. Complementary medicine means it is used along with standard medicine, also called conventional medicine. Alternative medicineis used in place of standard treatments. CAM treatments may include dietary supplements, megadose vitamins, herbal preparations,acupuncture, massage therapy, magnet therapy, spiritual healing, and meditation (See Figure 1, on page 4 for the major categories ofCAM therapies).INTRODUCTION5
Office of Cancer Complementary and Alternative Medicine6NCI CAM ANNUAL REPORT 2009
NCI’s Office of Cancer Complementary and Alternative Medicine (OCCAM) is acoordinating office responsible for: identifying gapsin the science and creating corresponding fundingopportunities for cancer CAM research; partnering with NCI program staff and other governmentaland nongovernmental organizations to increase thetesting of CAM approaches for cancer prevention,diagnosis, treatment, symptom management, andrehabilitation; developing communication productsfor various audiences concerning the investigationand use of these approaches; and helping to buildbridges between CAM practitioners and the cancerresearch community.OFFICE OF CANCER COMPLEMENTARY AND ALTERNATIVE MEDICINE7
OCCAM is part of the NCI Division of CancerTreatment and Diagnosis (DCTD). The division’smission is to improve the lives of the Americanpublic by discovering better ways to diagnose,assess, treat, and cure cancer through stimulating,coordinating, and funding a national programof cancer research. OCCAM’s programs andactivities complement DCTD’s mission and areenhanced by the other major programs andbranches within DCTD.FOCUSING ON BOTANICALS RESEARCHDuring FY 2009, OCCAM announced its newresearch priorities: Identifying novel therapeutics in the pharmacopeia of traditional medical systems as definedby the World Health OrganizationUsing complementary approaches to improvethe therapeutic ratio of standard and investigational anti-cancer therapiesResearch on lifestyle modifications (e.g., diet,exercise, mind-body approaches) for theirimpact on cancer outcomes (e.g., responseto conventional cancer therapy, survival)The new priorities were developed after OCCAMbecame part of the NCI Division of Cancer Treatment and Diagnosis (DCTD) in FY 2007. Thismove allowed OCCAM to develop a new focuson cancer treatment research in addition to itshistorical role of supporting the growth of CAMresearch in all of NCI’s divisions, offices, andcenters (DOCs). The three research prioritiesidentified by OCCAM represent areas of specialopportunities in the CAM field that do not overlapwith the DOCs’ existing research projects.BOTANICALS AND CANCER RESEARCH:CLINICAL TRIALS WORKSHOPIn July 2009, OCCAM convened a meeting attendedby more than 100 researchers, policymakers, andexperts for a two-day workshop designed to tacklethe topic of botanicals and clinical cancer research.Based on the type of expertise, the attendees wereassigned to one of the following six working groups: Targets, Pathways, and Networks ofPre-Clinical Models;Botanical Drug Issues;Clinical Trial Design and Implementation I;Clinical Trial Design and Implementation II;Role of Industry in Botanical DrugDevelopment; andObtaining Grant Funding for Botanical DrugResearch.Each working group was tasked to answer a seriesof questions about the challenges as well as theopportunities related to the current state ofbotanicals and cancer research.A number of ideas emerged about how to establishan effective and organized clinical trial researchinfrastructure in the United States. The image ofa pathway was used by some at the workshop asa way to describe how a botanical could movethrough the entire development spectrum: fromdiscovery and reliable harvesting, into preclinicalresearch at the bench, through to animal testing andhuman clinical trials, and ultimately to approval bythe U.S. Food and Drug Administration (FDA) asa cancer treatment in humans. The discussions fromthis meeting are being used by OCCAM to betterassess how to grow research in this topic and toimprove technical assistance to grant applicants.For more information, visit http://www.cancer.gov/cam/attachments/workshop agenda 09.pdf.8NCI CAM ANNUAL REPORT 2009
1999-2009NCI SIGNS RESEARCH AGREEMENT WITHCHINESE BOTANICAL INSTITUTEAfter the United States government signed a researchagreement with China to foster collaboration betweenresearchers studying integrative and TraditionalChinese Medicine (TCM) in both countries, oneof the first and most promising of these projectsis a partnership between the Kunming Institute ofBotany (KIB) of China Academy of Sciences andtwo groups at NCI.OCCAM began to oversee the growing collaborationafter a Memorandum of Understanding (MOU) wassigned between KIB and NCI in October 2008. KIBis supplying unique natural compounds from Chinese plants, while NCI’s Natural Products Branch(NPB) of the Developmental Therapeutics Program(DTP) will screen them for anticancer activity inNCI’s system of 60 human cancer cell lines. If anyof the botanical compounds show promise, moredrug analysis and development will follow.OCCAM SUPPORTS INTRAMURAL RESEARCHDuring FY 2009, OCCAM financially supportedtwo research projects within NCI’s Center forCancer Research (CCR). One research project ledby William Farrar, Ph.D., head of the CCR CancerStem Cell Section, identified two phytochemicals– parthenolide and gossypol – that target prostatecancer stem cells (CSC) and may be used to eradicateCSCs in such tumors.Thus far, parthenolide has been shown to affect:1. tumor incidence and latency in animal studies;2. signals associated with tumor proliferation andcancer cell invasion in micro-array studies; and3. prostate cancer initiation, progression, andmetastasis through altering transcription factor binding, which was found in protein/DNA array studies.OCCAM COMPLETES ITSFIRST DECADE AT NCIThe beginning of FY 2009 markedthe 10th anniversary of OCCAM’screation at NCI. During its firstdecade, OCCAM contributed to anddocumented the approximately 100 million growth of NCI’s CAMresearch portfolio. There was alsosignificant growth in the numberof clinical trials of CAM interventions, including landmark studieswhich for the first time providedsolid evidence that improvementsin lifestyle and dietary interventionsare feasible and can impact therecurrence of certain cancers.NCI’s commitment to CAMresearch and clinical practice hasbeen steadily supported, coordinated,and expanded by OCCAM over theyears and that mission continues.OFFICE OF CANCER COMPLEMENTARY AND ALTERNATIVE MEDICINE9
The following articles, that present the results ofthis research, were published in FY 2009 (PubMedIdentifier (PMID) numbers are provided for thecitations): Kawasaki BT, Farrar WL. Cancer stem cells,CD200 and immunoevasion. Trends Immunology, October 2008;29(10):464-8. Epub 2008Sep 3. PMID: 18775673.Kawasaki BT, Hurt EM, Kalathur M, DuhagonMA, Milner JA, Kim YS, Farrar WL. Effectsof the sesquiterpene lactone parthenolide onprostate tumor-initiating cells: An integratedmolecular profiling approach. Prostate, June 1,2009; 69(8):827-37. PMID: 19204913.Klarmann GJ, Hurt EM, Mathews LA, ZhangX, Duhagon MA, Mistree T, Thomas SB, FarrarWL. Invasive prostate cancer cells are tumorinitiating cells that have a stem cell-like genomicsignature. Clinical & Experimental Metastasis,2009; 26(5):433-46. Epub 2009 Feb 17.PMID: 19221883.Mathews LA, Crea F, Farrar WL. Epigeneticgene regulation in stem cells and correlation tocancer. Differentiation, July 2009;78(1):1-17.Epub 2009 May 14. Review. PMID: 19443100.In addition, for a third year, OCCAM has supported a CCR study on the Traditional ChineseMedicine (TCM) therapy called Sheng Qi Formula(SQF). O.M. “Zack” Howard, Ph.D., staff scientistand her team in the CCR Laboratory of MolecularImmunoregulation, Cancer and Inflammation Program conducted several studies during FY 2009 infollow up to work that was featured in a previousNCI CAM research annual report (An article onthe earlier research is on page 35 of the FY 2007CAM report which can be found at ortFY2007.pdf).10NCI CAM ANNUAL REPORT 2009These previous studies largely focused on the immunologic mechanisms of action of SQF. However, theCCR researchers’ recent experiments have begunto explore the direct effects of the TCM therapyon cancer cells. The resulting data from this year’swork indicate that the in vitro and in vivo effects ofSQF on the 4T1 breast cancer model are due to theinduction of apoptosis through the mitochondrialpathway.OCCAM PROGRAMSRESEARCH DEVELOPMENT ANDSUPPORT PROGRAMNCI sponsored 387 cancer CAM research projectsin FY 2009, each of which are managed withinthe various Divisions and Centers of the Institute.OCCAM’s Research Development and SupportProgram (RDSP) staff manages a portion of thisportfolio and works with other program staffthroughout NCI, assists investigators in identifyingfunding opportunities, and provides guidance in thepre- and post-review periods of grant application.The staff also coordinates programs and initiativesdesigned to stimulate research in cancer CAM aswell as activities to develop the foundation of thescience in cancer CAM research.Isis Mikhail, M.D., M.P.H., Dr.P.H. was namedas RDSP Program Director in November 2008.Dr. Mikhail received her medical degree from CairoUniversity Medical School. She then received herMPH and DrPH degrees in Epidemiology andInternational Health from the University ofAlabama at Birmingham. Before coming toOCCAM, Dr. Mikhail was a program director,epidemiologist and acting branch chief at theClinical and Translational Epidemiology Branch(CTEB) of the NCI Division of Cancer Controland Population Sciences (DCCPS).
Under Dr. Mikhail’s leadership, OCCAM reissuedthe program announcement (PA) PA-09-167“Developmental Projects in ComplementaryApproaches to Cancer Care and Treatment” inApril 2009. This PA solicits grant applications toencourage and support the development of basicand clinical complementary cancer research projects(prevention, therapeutic, and palliative) through theexploratory/developmental research grant (R21)award mechanism.For more information, A-09-167.html.In addition, OCCAM initiated a new small grantR03 funding opportunity announcement. This announcement, PA-09-168 offered R03 grant awardsfor researchers interested in starting small pilot andfeasibility studies of CAM therapies and practices.Through this mechanism, studies can be fundedthat generate data needed for conducting largerscientific studies of CAM. OCCAM seeks toencourage investigators to initiate research in areasnot typically explored in larger studies funded byother grant mechanisms, such as R01 and R21awards. Outreach to international audienceswas conducted for this PA. Dr. Fazlul Sarkar “A Novel and TargetedApproach to Inhibit Invasion and Angiogenesis” (R01CA131151-02S1). Wayne StateUniversity, Detroit, Michigan.Dr. Yung-Chi Cheng “Nucleoside Analogs asAnticancer Compounds” (3R01CA06347714S1). Yale University.OCCAM also provided an administrative supplement to the Radiation Therapy Oncology Group,Community Clinical Oncology Program (CCOP)Research Base (CA037422) to support componentsof a phase II/III study comparing acupuncture-liketranscutaneous electrical nerve stimulation(ALTENS) versus pilocarpine in treating earlyradiation-induced xerostomia (dry mouth).COMMUNICATIONS AND OUTREACHPROGRAMOCCAM’s Communications and Outreach Program(COP) develops and disseminates informationabout NCI program initiatives and fundingopportunities, workshops and other events,and educational materials through OCCAM’spublications and Web site (http://www.cancer.gov/cam).For more information, A-09-168.html.Funding CAM Research with Stimulus Act FundsOCCAM successfully proposed funding from theAmerican Recovery and Reinvestment Act (ARRA)of 2009 for three new supplements to grants in itsportfolio. The ARRA awardees were chosen, inpart, because they were addressing highly significant areas of cancer research: Dr. Rakesh Srivastava “Chemoprevention ofPancreatic Cancer by EGCG”(3R01CA125262-02S1). University of TexasHealth Center at Tyler.This program also assesses the opinions, interests,and informational needs of cancer researchers,CAM practitioners, and cancer patients regardingCAM research through surveys, public commentsessions, and focus groups. Results from theseexplorations are used to guide outreach efforts tothese communities.Assessing Cancer Patients Information NeedsIn FY 2009, COP made a commitment to expandits outreach and communication efforts to cancerpatients and produce additional resources that fillthe existing gaps in patients’ information needs.OFFICE OF CANCER COMPLEMENTARY AND ALTERNATIVE MEDICINE11
In order to develop resources that best serve theneeds of patients, OCCAM began a qualitativeneeds assessment to identify the CAM issues andtopics most important to cancer patients. Theneeds assessment started by targeting health careprofessionals who work closely with patients,including patient educators, social workers, nurses,physicians, and CAM practitioners. The information collected in OCCAM’s assessment will shapea dialogue about cancer patients’ needs related toCAM. It will also help NCI determine high priority areas for new patient-focused publications andresources.This exhibit better promotes the mission ofOCCAM and gives NCI a larger, more integralpresence at key cancer CAM meetings, events, andsymposia. Other major communication activities in FY 2009included: Redesign of Health Information and About Ussections of the OCCAM website, along withusability testing of entire website.Creating a Wikipedia entry on /cam information occam fall2009.html COP also published the following publications inFY 2009: NCI’s Annual Report on Complementary andAlternative Medicine: Fiscal Year 2008http://www.cancer.gov/cam/attachments/fy2008 CAM annual report.pdfNCI CAM News – Spring ng/home.htmlNCI CAM News – Fall fall2009 OCCAM newsletter home.htmlIn addition to sending staff and publications to thenumerous professional meetings listed below, COPimproved OCCAM’s outreach efforts by unveilinga new exhibit on NCI CAM research in FY 2009.12NCI CAM ANNUAL REPORT 2009 Frontiers in Integrative Oncology; AmericanCollege for Advancement in Medicine; LasVegas, NV; October 15-19, 2008 (OCCAMstaff attending: Shea Buckman)5th International Conference of the Society forIntegrative Oncology; Atlanta, GA; November20-21, 2008 (OCCAM staff attending: SheaBuckman, Dr. Isis Mikhail, Dr. Dan Xi)Evidence-based Complementary and Alternative Cancer Therapies Conference; West PalmBeach, FL; January 8-10, 2009 (OCCAM staffattending: Shea Buckman)8th Annual Oxford International Conferenceon the Science of Botanicals; Oxford, MS;April 2009 (OCCAM staff attending: SheaBuckman, Dr. Isis Mikhail)North American Research Conference onComplementary and Integrative Medicine;Minneapolis, MN; May 2009; (OCCAM staffattending: Shea Buckman, CommanderColleen Lee, Dr. Dan Xi)Oncology Nursing Society (OCCAM staffattending: Commander Colleen Lee)American Society of Clinical Oncology(OCCAM staff attending: Dr. Farah Zia)American Association of Family Physicians(materials only)COP CollaborationsEach fiscal year, groups around NCI request theexpertise of the COP staff. In FY 2009, COP: Assisted the NCI Office of Partnerships andDissemination Initiatives’ Multicultural MediaOutreach Program with developing an articleon CAM titled: “Interested in Complementary
and Alternative Medicine for Cancer? Talkwith Your Doctor” for NCI’s Lifelines, abiweekly column outreaching to Hispanic andAfrican American community newspapersacross the country. The CAM article was madeavailable to the BlackPressUSA.com via theNational Newspaper Publishers Associationand Journey to Wellness, a radio media brandthat provides health care and health literacyinformation through syndicated radio programming on public radio stations and onthe CNN Radio network. Worked with the NCI Cancer InformationService’s (CIS) to edit the CAM script for therecorded message on CAM offered throughthe 1-800-4-CANCER telephone line.The CAM script is one of six automatedtreatment messages. Provided content review of CAM articleswritten for the NCI Cancer Bulletin biweeklynewsletter, which reaches approximately52,000 subscribers. In FY 2009, COPparticipated in the following article reviews:– Harnessing the Biological Activity of NaturalProducts– Chemotherapy Provides Longer Survivalthan Enzyme Therapy for Pancreatic Cancer– Dietary Supplements and Cancer Treatment:A Risky Mixture– Researchers Urge Caution and GreaterScrutiny of Colon-related CAM Treatments.In FY 2009, cancer patient advocates were involved in the review of NCI’s CAM AnnualReport. OCCAM solicited feedback from fourConsumer Advocates in Research and RelatedActivities (CARRA) members who agreed to review a draft of the FY 2008 report. These members provided comments on whether the documentwas easy to read, contained relevant informationto the cancer patient community, or omitted topicsof patient interest. The feedback from theseCARRA members improved the quality of theNCI’s Annual Report on Complementary andAlternative Medicine: Fiscal Year 2008.PRACTICE ASSESSMENT PROGRAMOCCAM’s Practice Assessment Program (PAP)reviews information on cancer patients treatedwith alternative therapies. PAP manages the NCIBest Case Series (BCS) Program, which providesan opportunity for CAM practitioners to submitretrospective case reports regarding cancer CAMtreatments used in their settings. Practitioners areasked to submit patient records for evaluation byexperts i
Traditional Chinese Medicine, Tibetan Medicine . ENERGY THERAPIES . DEFINITION: Energy therapies involve the use of energy fields. There are two types: Biofield therapies are intended to affect energy fields that purportedly surround and penetrate the human body. The existence of such
Ovarian cancer is the seventh most common cancer among women. There are three types of ovarian cancer: epithelial ovarian cancer, germ cell cancer, and stromal cell cancer. Equally rare, stromal cell cancer starts in the cells that produce female hormones and hold the ovarian tissues together. Familial breast-ovarian cancer
As the Chair and Co-Chair of the Kansas Cancer Partnership (KCP), we are pleased to provide . you with the 2017-2021 Kansas Cancer Prevention and Control Plan. This plan is the result of . Breast Biopsies Breast Cancer Cervical Cancer Colorectal Cancer Lung Cancer Prostate Cancer. Post-Diagnosis & Quality of Life throughout the Cancer Journey.
cancer, pancreatic cancer, breast cancer, lung cancer, liver cancer, kidney cancer, brain cancer & brian tumors, lymphoma, blood diseases, bone cancer & all types of viruses Used externally as a skin cancer treatment, treating carcinoma, melanoma, warts, moles & as a drawing salve People with in-operable cancers sent home to die have used black
Breast Cancer Breast cancer is one of the most common forms of cancer among women (40,290 in 2015). It is second only to lung cancer as a cause of cancer deaths in American women, One-third of women with breast cancer die from breast cancer, One out of every eight women will be
11/15/2011 4 Lung Cancer Facts Lung cancer accounts for more deaths than any other cancer in both men and women. Since 1987, more women have died each year from lung cancer than from breast cancer. Lung cancer causes more deaths than the next three common cancers combined (colon, breast, prostate). Smoking contributes to 80% and 90% of lung cancer deaths in
Cancer incidence—Cancer deaths 2. Pathogenetic factors: a balance of risks 3. Clinical effects of cancer 4. Death in cancer 5. Grading and Staging 6. Diagnosis? Cancer Age Environment Heredity-cancer mortality peak 55-75-under age 15, cancer causes approx. 10% of all deaths-cancer w/ ag
Breast cancer development In the United States, breast cancer is the most common cancer diagnosed in women (excluding skin cancer). Men may also develop breast cancer, but less than 1% of all people with breast cancer are men. Breast cancer begins when healthy cells in the breast change and grow uncontrollably, forming a mass called a tumor.
Tier 3: Florida-based cancer centers in pursuit of designation as either a NCI-designated Cancer Center or NCI-designated Comprehensive Cancer Center Currently, there are three participating cancer centers: H. Lee Moffitt Cancer Center, University of Florida Shands Cancer Hospital, and University of Miami Sylvester Comprehensive Cancer Center.
